Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Athenex, Inc.ATNX · Entity 113753 | General Counsel, SVP Admin. | August 03, 2021 | August 05, 2021 |
| Kura Oncology, Inc.KURA · Entity 4871 | Chief Legal Officer | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Athenex, Inc.
Report date August 03, 2021 · Filed August 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2031-08-03 | Direct | 37,500 |
Reported balance
After 2021-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-03 · Grant · Acquired 37,500 · Balance 37,500 F4: This option vests in four equal annual installments beginning on August 3, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.50 · Expires 2025-05-22 | Direct | 128,000 |
Reported balance
Holding disclosure · report date 2021-08-03 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 128,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2027-06-13 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2021-08-03 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 15,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.30 · Expires 2028-03-27 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2021-08-03 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 20,000 F1: This option vests in four equal annual installments beginning on March 27, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2030-08-05 | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2021-08-03 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 60,000 F2: This option vests in four equal annual installments beginning on August 5, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.26 · Expires 2030-08-27 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2021-08-03 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 15,000 F3: This option vests in four equal annual installments beginning on August 27, 2021. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 37,500 |
Reported balance
After 2021-08-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-08-03 · Grant · Acquired 37,500 · Balance 37,500 F5: Each restricted stock unit represents a contingent right to receive one share of stock. F6: The restricted stock units vest in four equal annual installments beginning on August 3, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in four equal annual installments beginning on March 27, 2019.
F2: This option vests in four equal annual installments beginning on August 5, 2021.
F3: This option vests in four equal annual installments beginning on August 27, 2021.
F4: This option vests in four equal annual installments beginning on August 3, 2022.
F5: Each restricted stock unit represents a contingent right to receive one share of stock.
F6: The restricted stock units vest in four equal annual installments beginning on August 3, 2022.
Kura Oncology, Inc.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 195,444 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Sale · Disposed 31,487 · Balance 195,444 F1: The shares sold were acquired by the Reporting Person upon vesting of restricted stock units during the period from January 26, 2024 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2026. F2: This transaction was executed in multiple trades at prices ranging from $12.44 to $12.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares sold were acquired by the Reporting Person upon vesting of restricted stock units during the period from January 26, 2024 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $12.44 to $12.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 20:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 31,487 | $12.63 | $397,680.81 |
DisclosureSEC source: 0001193125-26-361184 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,444 F1 · kind: The shares sold were acquired by the Reporting Person upon vesting of restricted stock units during the period from January 26, 2024 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.44 to $12.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,256 | $9.38 | $21,160.15 |
DisclosureSEC source: 0001193125-26-232546 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 226,931 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. F2 · shares: 2,256 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $9.28 to $9.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,777 | $8.46 | $40,416.76 |
DisclosureSEC source: 0001193125-26-025301 · ownership.xml · nonDerivative · entry 3 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,931 F3 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,335 | $8.46 | $19,755.73 |
DisclosureSEC source: 0001193125-26-025301 · ownership.xml · nonDerivative · entry 2 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,708 F2 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,096 | $8.46 | $34,655.03 |
DisclosureSEC source: 0001193125-26-025301 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,043 F1 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 100,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004562 · ownership.xml · derivative · entry 2 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004562 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,139 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 8,804 | $11.18 | $98,401.43 |
DisclosureSEC source: 0001193125-25-283568 · ownership.xml · nonDerivative · entry 2 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,139 F1 · kind: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 48,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-283568 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,943 Read SEC document |
| September 29, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 8,805 | $8.94 | $78,736.07 |
DisclosureSEC source: 0001193125-25-223666 · ownership.xml · nonDerivative · entry 2 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,043 F1 · kind: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on September 27, 2025, resulting in the vesting of 1/6th of the underlying shares. Read SEC document |
| September 27, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 48,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-223666 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,848 Read SEC document |
| May 19, 2025 Filed May 19, 2025 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,559 | $5.96 | $9,291.64 |
DisclosureSEC source: 0000950170-25-074660 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,948 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 31, 2024. F2 · shares: 1,559 shares were acquired on May 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,844 | $7.87 | $38,131.48 |
DisclosureSEC source: 0000950170-25-010120 · ownership.xml · nonDerivative · entry 2 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,948 F2 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,437 | $7.87 | $19,183.82 |
DisclosureSEC source: 0000950170-25-010120 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,792 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 92,500 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0000950170-25-002062 · ownership.xml · derivative · entry 2 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2035-01-01 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 46,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002062 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,229 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/26, 1/26/27, 1/26/28 and 1/26/29. Read SEC document |
| May 20, 2024 Filed May 20, 2024 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,615 | $22.15 | $57,916.24 |
DisclosureSEC source: 0000950170-24-062585 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,979 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2023. F2 · shares: 2615 shares were acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.06 to $22.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.direct: The reported sale of 2,615 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2023. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,053 | $17.80 | $36,544.43 |
DisclosureSEC source: 0000950170-24-009495 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,979 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/23. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 92,500 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0000950170-24-001847 · ownership.xml · derivative · entry 2 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2034-01-01 F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 46,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001847 · ownership.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,032 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/25, 1/26/26, 1/26/27 and 1/26/28. F2 · balance_after: Includes 1,657 shares acquired on May 17, 2023 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:13 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 138,750 | $0.00 Strike: $11.99 | $0.00 |
DisclosureSEC source: 0001209191-23-011287 · doc4.xml · derivative · entry 2 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,750 Underlying: Common Stock · 138,750 shares Expires 2033-02-15 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:13 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 23,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011287 · doc4.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,125 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/24, 1/26/25, 1/26/26 and 1/26/27. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 21:53 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,100 | $15.22 | $31,964.52 |
DisclosureSEC source: 0001209191-22-057874 · doc4.xml · nonDerivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2022. F2 · shares: 2,100 shares were acquired on November 17, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $15.08 to $15.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 21:13 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 192,000 | $0.00 Strike: $17.51 | $0.00 |
DisclosureSEC source: 0001209191-21-060952 · doc4.xml · derivative · entry 1 Bair Teresa Brophy · CIK 0001813058 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,000 Underlying: Common Stock · 192,000 shares Expires 2031-10-17 F1 · derivative.exercise_date: 1/4th of the shares vest on the one year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:26 UTC | Athenex, Inc. ATNX · Entity 113753 | GrantRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-050011 · doc4.xml · derivative · entry 7 Bair Teresa Brophy · CIK 0001813058 · General Counsel, SVP Admin. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on August 3, 2022. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on August 3, 2022. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:26 UTC | Athenex, Inc. ATNX · Entity 113753 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001209191-21-050011 · doc4.xml · derivative · entry 6 Bair Teresa Brophy · CIK 0001813058 · General Counsel, SVP Admin. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2031-08-03 F4 · derivative.exercise_date: This option vests in four equal annual installments beginning on August 3, 2022. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:09 UTC | Athenex, Inc. ATNX · Entity 113753 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.26 | $0.00 |
DisclosureSEC source: 0001209191-20-048745 · doc4.xml · derivative · entry 5 Bair Teresa Brophy · CIK 0001813058 · General Counsel, SVP Admin. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-08-27 F4 · derivative.exercise_date: This option vests in four equal annual installments beginning on August 27, 2021. Read SEC document |
| August 05, 2020 Filed Aug 8, 2020 00:46 UTC | Athenex, Inc. ATNX · Entity 113753 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-20-045792 · doc4.xml · derivative · entry 4 Bair Teresa Brophy · CIK 0001813058 · General Counsel, SVP Admin. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-08-05 F3 · derivative.exercise_date: This option vests in four equal annual installments beginning on August 5, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.